TY  - CHAP
M1  - Book, Section
TI  - The Pathology of Bronchogenic Carcinoma
A1  - Litzky, Leslie A.
A2  - Grippi, Michael A.
A2  - Antin-Ozerkis, Danielle E.
A2  - Dela Cruz, Charles S.
A2  - Kotloff, Robert M.
A2  - Kotton, Camille Nelson
A2  - Pack, Allan I.
PY  - 2023
T2  - Fishman’s Pulmonary Diseases and Disorders, 6e
AB  - The  development  of  new  classes  of  drugs  and  targeted  therapy  for  lung  cancer  prompted  an  extensive  reevaluation  of  the  pathologic  classification  of  bronchogenic  carcinoma  but  did  not  diminish  the  significance  and  impact  of  the  histologic  classification  of  bronchogenic  carcinoma.  Rather  than  marginalizing  the  traditional  role  of  the  pathologist  in  lung  cancer  treatment,  the  advent  of  what  has  been  termed  “personalized”  or  “precision”  medicine  has  only  made  pathologic  assessment  more  crucial  to  patient  management.1,2  The  clinical  necessity  of  providing  rapid  and  concurrent  molecular/immunologic  analysis  along  with  a  histologic  diagnosis  has  placed  the  anatomic  pathologist  in  the  additional  central  strategic  management  role  of  tumor  tissue  processing  and  evaluation,  in  addition  to  frequent  consultation  on  optimal  sample  acquisition.  This  chapter  focuses  on  the  major  histologic  subtypes  of  malignant  pulmonary  epithelial  tumors  and  includes  carcinoid  tumors,  sarcomatoid  carcinoma,  and  salivary  gland  tumors.  Other  unusual  tumors,  both  benign  and  malignant,  are  covered  in  a  separate  chapter,  and  there  is  another  chapter  on  the  genetic  and  molecular  changes  in  lung  cancer.  The  extremely  rapid  pace  of  developments  in  molecular  diagnostics  and  therapy  makes  it  quite  difficult  to  make  enduring  summary  statements  about  the  prognostic  and  therapeutic  implications  for  specific  histologic  subtypes.  New  molecular  and  immunologic  insights  are  leading  to  entirely  new  classes  of  drugs  that  are  continuously  impacting,  and  in  some  cases  dramatically  improving,  overall  survival  statistics.  The  intent  of  this  chapter,  therefore,  is  to  provide  a  broad  overview  of  the  current  histologic  classification  and  to  provide  a  deeper  understanding  of  the  critical  issues  regarding  the  preanalytic  steps  of  sampling,  processing,  and  evaluating  lung  cancer  specimens  for  molecular  analysis.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/20
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1195012988
ER  -